Martin Shkreli violated his lifetime pharma industry ban, the FTC and states say in a contempt claim. A lifetime ban is only worth the enforcement behind it, and this is that test. Pharma conduct risk

What happened: The FTC and states filed a contempt claim saying Martin Shkreli violated his lifetime ban from the pharmaceutical industry. He was banned after a trial found he organized an illegal scheme to monopolize the drug Daraprim. Why it matters: The contempt claim asks the court to act on the alleged violation of the ban imposed after the Daraprim monopoly finding. Coverage: 10 outlets in 24h

FTC and states allege Martin Shkreli violated his lifetime pharma ban, triggering contempt claim.

FTC and states allege Martin Shkreli violated his lifetime pharma ban, triggering contempt claim. — impact context not separately stored; see What changed.